Literature DB >> 6693666

Allergic bronchopulmonary aspergillosis in cystic fibrosis.

P Laufer, J N Fink, W T Bruns, G F Unger, J H Kalbfleisch, P A Greenberger, R Patterson.   

Abstract

One hundred patients with CF were screened for ABPA. Forty-eight male patients and 52 female patients with age range of 2 to 34 yr (mean 14.2) were studied. Patients were evaluated for skin reactivity and serum precipitating antibodies to Af, predominant sputum organisms, total blood eosinophil levels, total serum IgE, and Af-specific IgE and IgG, as well as abnormalities of pulmonary function and chest x-ray films. Careful evaluation of all patients with CF demonstrated that 10% had features indicative of ABPA, which is another potentially destructive pulmonary disorder. Thus careful evaluation of patients with CF, especially those with asthma, may be rewarding in uncovering a disorder that may slow progression of CF when it is appropriately treated.

Entities:  

Mesh:

Year:  1984        PMID: 6693666     DOI: 10.1016/0091-6749(84)90482-2

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  32 in total

1.  Lack of cystic fibrosis transmembrane conductance regulator in CD3+ lymphocytes leads to aberrant cytokine secretion and hyperinflammatory adaptive immune responses.

Authors:  Christian Mueller; Sofia A Braag; Allison Keeler; Craig Hodges; Mitchell Drumm; Terence R Flotte
Journal:  Am J Respir Cell Mol Biol       Date:  2010-08-19       Impact factor: 6.914

2.  Cystic fibrosis transmembrane conductance regulator (CFTR) gene mutations in allergic bronchopulmonary aspergillosis.

Authors:  P W Miller; A Hamosh; M Macek; P A Greenberger; J MacLean; S M Walden; R G Slavin; G R Cutting
Journal:  Am J Hum Genet       Date:  1996-07       Impact factor: 11.025

Review 3.  Allergic bronchopulmonary aspergillosis in patients with cystic fibrosis.

Authors:  A P Knutsen; R G Slavin
Journal:  Clin Rev Allergy       Date:  1991 Spring-Summer

4.  Allergy-important advances in clinical medicine: immunologic aspects of cystic fibrosis.

Authors:  E J Lee; D C Heiner
Journal:  West J Med       Date:  1984-10

Review 5.  Off-Label Uses of Omalizumab.

Authors:  David El-Qutob
Journal:  Clin Rev Allergy Immunol       Date:  2016-02       Impact factor: 8.667

Review 6.  Clinical significance of microbial infection and adaptation in cystic fibrosis.

Authors:  Alan R Hauser; Manu Jain; Maskit Bar-Meir; Susanna A McColley
Journal:  Clin Microbiol Rev       Date:  2011-01       Impact factor: 26.132

Review 7.  Allergic bronchopulmonary aspergillosis.

Authors:  Richard B Moss
Journal:  Clin Rev Allergy Immunol       Date:  2002-08       Impact factor: 8.667

Review 8.  Cystic fibrosis. Infection and immunity to Pseudomonas.

Authors:  R U Sorensen; R L Waller; J D Klinger
Journal:  Clin Rev Allergy       Date:  1991 Spring-Summer

Review 9.  Aspergillus in the lung: diverse and coincident forms.

Authors:  Susan J Buckingham; David M Hansell
Journal:  Eur Radiol       Date:  2003-05-29       Impact factor: 5.315

10.  Serum antibodies to Aspergillus fumigatus catalase in patients with cystic fibrosis.

Authors:  H Schønheyder; T Jensen; I H Laessøe; N Høiby; C Koch
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1988-02       Impact factor: 3.267

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.